MAR-ALLOPURINOL TABLET

Pajjiż: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

ALLOPURINOL

Disponibbli minn:

MARCAN PHARMACEUTICALS INC

Kodiċi ATC:

M04AA01

INN (Isem Internazzjonali):

ALLOPURINOL

Dożaġġ:

200MG

Għamla farmaċewtika:

TABLET

Kompożizzjoni:

ALLOPURINOL 200MG

Rotta amministrattiva:

ORAL

Unitajiet fil-pakkett:

30/100/500/1000

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

ANTIGOUT AGENTS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0103654002; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2012-11-22

Karatteristiċi tal-prodott

_ _
_MAR-Allopurinol PM_
_ _
_ _
_Page 1 of 26_
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION PR
MAR-ALLOPURINOL
Allopurinol Tablets
Tablets, 100, 200 and 300 mg, oral
USP
Xanthine Oxidase Inhibitor
Marcan Pharmaceuticals Inc.
2 Gurdwara Road, Suite #112
Ottawa, Ontario K2E 1A2
Submission Control Number: 265172
Date
of
Initial
Authorization:
NOV
22,
2012
Date
of
Revision:
JUL
13,
2022
_ _
_MAR-Allopurinol PM_
_ _
_ _
_Page 2 of 26_
_ _
RECENT MAJOR LABEL CHANGES
3 Serious Warnings and Precautions Box
07/2022
4 Dosage and Administration, 4.2 Recommended Dose and Dosage
Adjustment
07/2022
7 Warnings and Precautions
07/2022
7 Warnings and Precautions, 7.1.4 Geriatrics
07/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
............................................................................................
2
TABLE OF CONTENTS
...............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
4
1
INDICATIONS
...............................................................................................................
4
1.1
Pediatrics
...................................................................................................................
4
1.2
Geriatrics
....................................................................................................................
4
2
CONTRAINDICATIONS
..................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
.............................................................. 5
4
DOSAGE AND ADMINISTRATION
..................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
.......................................................... 5
4.5
Missed Dose
.................